Marius Pharmaceuticals, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
15
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 20, 2026The maintenance fee for Ganaxolone for Use in Treatment of Status Epilepticus (US 11,679,117) comes due Dec 20, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 1 fee due Jan 18, 2027The maintenance fee for Ganaxolone for Use in Treating Tuberous Sclerosis Complex (US 11,701,367) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
- 1 fee due Feb 27, 2027The maintenance fee for Methods of Treating Certain Depressive Disorders and Delirium Tremens (US 10,391,105) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
- 2 fees due Sep 3, 2027
- 2 fees due Nov 5 to 14, 2027 · next Nov 5
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,367,651 | Solid Ganaxolone Formulations and Methods for the Making and Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 8,618,087 | Solid Ganaxolone Formulations and Methods for the Making and Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,029,355 | Solid Ganaxolone Compositions and Methods for the Making and Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,056,116 | Liquid Ganaxolone Formulations and Methods for the Making and Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,452,176 | Solid Ganaxolone Compositions and Methods for the Making and Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,071,740 | Method of Treatment Using Nanoparticulate Ganaxolone Formulations In force · Medium confidence | In force | Medium confidence | |
| US 7,858,609 | Solid Ganaxolone Formulations and Methods for the Making and Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 8,022,054 | Liquid Ganaxolone Formulations and Methods for the Making and Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,017,728 | Stable Corticosteroid Nanoparticulate Formulations and Methods for the Making and Use thereof In force · Medium confidence | In force | Medium confidence | |
| US 8,455,002 | Stable Corticosteroid Nanoparticulate Formulations And Methods For The Making And Use Thereof In force · Medium confidence | In force | Medium confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 2 abandoned · 4 no status recorded